Revance Therapeutics (Revance Therapeutics) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Apr. 28, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Revance Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Revance Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Revance Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Revance Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revance Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Revance Therapeutics (NAS:RVNC) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Revance Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics (Revance Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (NAS:RVNC) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

RTI:Germany

Address

1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203

Website

https://www.revance.com

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Executives

Dwight Moxie	officer: SVP, GC & Secretary	7555 GATEWAY BOULEVARD, NEWARK CA 94560
Mark J Foley	director	ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Tobin Schilke	officer: Chief Financial Officer	7000 SHORELINE COURT, #371, SOUTH SAN FRANCISCO CA 94080
Carey Oconnor Kolaja	director	C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 1001, NASHVILLE TN 37203
Dustin S Sjuts	officer: President	7555 GATEWAY BLVD, NEWARK CA 94560
Vlad Coric	director	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Aubrey Rankin	director	C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD, NEWARK CA 94560
Angus C. Russell	director	C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Olivia C Ware	director	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Chris Nolet	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Jill Beraud	director	C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO CA 94111
L Daniel Browne	director, officer: CEO and President	7555 GATEWAY BOULEVARD, NEWARK CA 94560
Cyril Allouche	officer: Principal Financial Officer	7555 GATEWAY BLVD., NEWARK CA 94560
Lauren P Silvernail	officer: CFO, Seretary & EVP Corp Dev.	15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Caryn Gordon Mcdowell	officer: SVP, GC & Secretary	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080